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Abstract
Purpose of Review The purpose of this review was to sum-
marise current evidence that some environmental chemicals
may be able to interfere in the endocrine regulation of energy
metabolism and adipose tissue structure.
Recent Findings Recent findings demonstrate that such
endocrine-disrupting chemicals, termed “obesogens”, can
promote adipogenesis and cause weight gain. This includes
compounds to which the human population is exposed in
daily life through their use in pesticides/herbicides, indus-
trial and household products, plastics, detergents, flame
retardants and as ingredients in personal care products.
Animal models and epidemiological studies have shown
that an especially sensitive time for exposure is in utero
or the neonatal period.
Summary In summarising the actions of obesogens, it is
noteworthy that as their structures are mainly lipophilic,
their ability to increase fat deposition has the added conse-
quence of increasing the capacity for their own retention.
This has the potential for a vicious spiral not only of in-
creasing obesity but also increasing the retention of other
lipophilic pollutant chemicals with an even broader range
of adverse actions. This might offer an explanation as to
why obesity is an underlying risk factor for so many dis-
eases including cancer.
Keywords Adipogenesis . Bisphenol A . Diethylstilbestrol .
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Introduction
The endocrine system plays a fundamental role in regulating
the metabolism of fats, carbohydrates and proteins and in en-
suring that these fuels provide for the energy needs of the body
at all times. Hormones are responsible for storage of excess
fuel in times of plenty and mobilisation of fuel in times of
need, andmost notably inmaintaining constant levels of blood
glucose. Any alteration to these hormonally driven processes
can be expected to lead to an imbalance in metabolism. The
main store of energy in the body is provided by fat held in
adipocytes in the adipose tissue, and it is now recognised that
the adipose tissue is also under endocrine control and can itself
act as an endocrine organ capable of secreting hormones [1].
Interference in hormonal control of adipose tissue functions
can therefore also lead to inappropriate deposits of fat and,
hence, obesity.
Over recent years, many environmental chemicals have
been shown to disrupt the actions of hormones and have been
termed endocrine-disrupting chemicals (EDCs) or endocrine
disruptors [2•]. Although much of the research has focused on
disruption of reproduction through interference with steroid
hormone actions and on disruption to thyroid hormone action
[2•], there are increasing reports that some EDCs can also
interfere with regulatory processes in metabolism and in the
control of adipocyte function, resulting in imbalances in the
regulation of body weight, which can lead to obesity [3•, 4•,
5•]. Such chemicals have been termed “obesogens” [6, 7•].
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Increase in obesity, defined as a body mass index of over
30 kg/m2, has become a global problem over recent decades.
Over 20% of adults are now obese in the UK and over 30% of
adults are obese in the USA [8•]. Furthermore, obesity in
children is also increasing in westernised countries, and in
the USA, around 20% of children aged 3–17 years are obese
[8•]. Although there are genetic determinants which lead to
inherited predisposition, and there are environmental influ-
ences from excessive food intake combined with lack of ex-
ercise in modern life, these alone cannot account for the cur-
rent disease trends. This review will present evidence that
EDCs may contribute to obesity through interfering with the
control of energy metabolism and adipose tissue regulation,
causing an altered balance towards weight gain and obesity,
despite normal diet and exercise patterns.
Sources of Endocrine Disruptors
An endocrine disruptor has been defined as “an exogenous
substance that causes adverse health effects in an intact organ-
ism, and/or its progeny, consequent to changes in endocrine
function” [9]. Some of these compounds are present in nature
(e.g. plant phytoestrogens), but the majority are synthetic
chemicals which have been released by human activities into
the environment without any prior knowledge of their effects
on ecosystems or human health. The human population is now
ubiquitously exposed to such chemicals in daily life, in indoor
as well as outdoor environments, through their use in pesti-
cides/herbicides, industrial and household products, plastics,
detergents, flame retardants and as ingredients of personal
care products [2•]. Intake to the human body may be oral,
inhalation or dermal absorption [2•]. Figure 1 indicates some
of the subset of endocrine disruptors which have been shown
to possess obesogenic properties: their origins and endocrine-
disrupting activities are outlined below, and the remainder of
the review will discuss the evidence that they possess also
obesogenic properties.
& Tributyltin (TBT) is an environmental contaminant from
its use as a biocide in antifouling paints applied to the hulls
of ships, and it has been reported to cause imposex in
molluscs and to masculinise female fish [10]. TBT can
inhibit aromatase, which is the enzyme responsible for
the conversion of testosterone into estrogens [11, 12].
& Diethylstilbestrol (DES) is a synthetic non-steroidal
oestrogen that was first synthesised in 1938 [13] and then
prescribed to several million women between 1940 and
1971 to prevent threatened miscarriage in the first trimes-
ter [14], before untoward side effects stopped further pre-
scription [15]. It has also been used to enhance fertility in
farm animals used for meat supply [15].
& Persistent organic pollutants (POPs) are stable man-made
compounds that do not readily degrade and tend to persist
in the environment and bioaccumulate [2•]. Many are li-
pophilic and therefore become stored in fatty tissues, pass-
ing up the food chain in animal fat. From use as an insec-
ticide, both dichlorodiphenyltrichloroethane (DDT) and
its breakdown product dichlorodiphenyldichloroethylene
(DDE) remain widely present in human adipose tissue
[16] and are endocrine disrupters [2•]. Polychlorinated
biphenyls (PCBs) are industrial POPs which are also
widely measurable in human adipose tissue [17] and have
been shown to be endocrine disrupters [2•].
& Bisphenol A and phthalates are used in the manufacture of
plastics. Bisphenol A (BPA) is used for its cross-linking
properties in the manufacture of polycarbonate plastics
and epoxy resins, which are now ubiquitous in consumer
products such as water bottles, linings of water pipes,
coatings on food and beverage cans, thermal paper and
dental sealants. It is listed as a high production volume
chemical by the Organisation for Economic Cooperation
and Development (OECD) [18]. It can leach out from
plastic containers [19] and has endocrine-disrupting prop-
erties [20, 21]. Phthalates are esters of phthalic acid and
are used mainly as plasticizers to increase the flexibility,
transparency and durability of plastic materials. They are
found in many consumer products including adhesives,
paints, packaging, children’s toys, electronics, flooring,
medical equipment, personal care products, air fresheners,
food products, pharmaceuticals and textiles. Many of the
phthalates are also listed by the OECD in their 2004 list of
high production volume chemicals [18] and possess
endocrine-disrupting properties [22, 23].
& Polybrominated diphenyl ethers (PBDEs) and
polybrominated biphenyls are widely used as flame retar-
dants. They are now detectable in human tissues [24] and
have endocrine-disrupting properties through interference
in thyroid function [25].
& 4-Nonylphenol is one of the long-chain alkyl phenols used
as a surfactant in industrial and domestic applications
worldwide which is listed as a high production chemical
by the OECD [18] and is an endocrine disrupter due to its
estrogenic activity [26].
& Parabens (alkyl esters of p-hydroxybenzoic acid) are used
as antimicrobial agents for the preservation of personal
care products, foods, pharmaceutical products and paper
products. They are widely present in human tissues in-
cluding breast tissue and have estrogenic properties [27].
& Phytoestrogens are produced naturally by plants and as
such are ingested by humans in the diet in edible plant
material. Isoflavones such as genistein and daidzein are
found in soybeans, legumes, lentils and chickpeas.
Phytoestrogens are so named for their estrogenic activity
[28]. On the general assumption that naturally occurring
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compounds are more beneficial than synthetic com-
pounds, phytoestrogens have been embraced much more
positively by society than the synthetic xenoestrogens,
and as such, potential benefits tend to have been
overemphasised compared with adverse effects, such as
those potentially related to obesity.
Developmental Susceptibility to Obesogenic EDCs
An especially sensitive time frame for exposure to obesogens
has been found to be either prior to birth in utero or in the
neonatal period [29]. Animal models have shown that expo-
sure of pregnant mice to TBT results in offspring which are
heavier than those not exposed [30]. Neonatal mice exposed
to the synthetic oestrogen DES have also been reported to
have increased body weight [31]. Figure 2 shows a represen-
tative photomicrograph at 4–6 months of age of control and
neonatal DES-treated female mice: the mice were treated on
days 1–5 of age with 1 μgDES/kg body weight/day, and obe-
sity was evident by 4–6 months of age [31]. This serves to
demonstrate the obesogenic consequences of exposure to a
potent oestrogen at an inappropriate developmental stage.
Other animal models have shown that exposure to some
PCB congeners [32], to BPA [33], to bisphenol S, an increas-
ingly used substitute for BPA [34•], and to a commercial mix-
ture of PBDEs [35] can also predispose animals to weight
gain. Post-weaning exposure of C57BL/6J mice to
methylparaben by oral gavage also increased adiposity [36•],
but such effects were not observed with the longer alkyl chain
butylparaben [36•]. This is in marked contrast to the positive
association observed for parabens between oestrogenic activ-
ity and longer alkyl chains [27].
The reported rise in obesity of children under 2 years of age
[37, 38] is also suggestive of alterations during development.
It would seem unlikely that such young children would have
been affected by eating so much more food and taking so
much less exercise than in previous generations, and current
explanations revolve around an altered environment in utero
or postnatally which is affecting fat deposition in early life
[4•]. This is backed by epidemiological evidence [39–41].
Studies of babies born to mothers who smoked tobacco during
pregnancy have been found to have a low birth weight, but
paradoxically to then be at increased risk of obesity [42], and
meta-analysis of multiple studies confirms that early-life ex-
posure to some components of tobacco smoke can lead to later
obesity [43]. A study of children in the Faroe Islands has
shown that prenatal exposure to PCBs and DDE contained
in dietary seafood is also associated with increased body
weight [44•]. Interestingly, the effects in this study showed a
non-monotonic response with the lower doses causing a great-
er weight gain, an effect which is consistent with many other
actions of the EDCswhere non-monotonic responses are com-
monly observed [45]. Other studies have shown that early-life
exposures to some POPs [46] and bisphenol A [47] are also
associated with increased body weight in young children.
Some studies suggest that such effects may even be
inherited through future generations without the need for fur-
ther exposure. Transgenerational studies have shown that
pregnant mice exposed to TBT produce offspring with greater
fat deposits, and this phenotype was found to be passed on to
the F3 generation, although there was no further TBT expo-
sure [48•]. Other heritable traits towards obesity in rodents
Fig. 1 Environmental endocrine
disruptors which have been
shown to possess obesogenic
properties, as discussed in this
review
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have been demonstrated following exposure to BPA and
phthalates (diethylhexyl and dibutyl) [49•] and DDT [50•].
Mechanisms of Action of Obesogenic EDCs
Obesogens cause weight gain by altering lipid homeostasis to
promote adipogenesis and lipid accumulation, and this may
occur through multiple mechanisms, outlined in Fig. 3. This
may occur through increasing the number of adipocytes, in-
creasing the size of adipocytes or altering the endocrine path-
ways responsible for the control of adipose tissue develop-
ment. In general, early developmental changes (in utero or
postnatally) involve an increase in adipocyte numbers, whilst
changes later in life during adulthood tend to involve mainly
an increase in the size of adipocytes [51]. Current evidence
suggests that adipocyte numbers are set by the end of child-
hood and that any increase in adipocyte numbers in early life
tends to be permanent [51]. This has profound consequences
for the timing of exposure to obesogens, implying that alter-
ations during early life would be passed on into adulthood,
which would not be reversed [4•]. Other mechanisms of inter-
ference by obesogens may involve altering hormones that
regulate appetite, satiety and food preferences, altering the
basal metabolic rate or altering the energy balance to favour
storage of calories. Finally, mechanisms may involve alter-
ations to insulin sensitivity and lipid metabolism in endocrine
tissues such as the pancreas, adipose tissue, liver, gastrointes-
tinal tract, brain or muscle.
At a molecular level, obesogens can act by interfering with
nuclear transcriptional regulators that control lipid flux and/or
adipocyte proliferation/differentiation, such as the peroxisome
proliferator-activated receptors (PPARα, PPAR-δ and
PPAR-γ) and steroid hormone receptors. These receptors all
function as ligand-activated transcription factors in that, after
binding ligands, they are enabled to bind to response elements
in the DNA and act to regulate specific patterns of gene ex-
pression [2•]. EDCs which can bind to these nuclear receptors
have the potential to cause inappropriate responses, including
obesity.
Obesogens Acting through Interference with PPARs
PPARs can bind a wide range of unsaturated fatty acids and
therefore act as lipid sensors to regulate lipid homeostasis.
PPARγ functions in energy storage through its regulatory ac-
tions on adipogenesis and has therefore been defined as a
master regulator of fat cell development [52]. PPARs act by
heterodimerisation with retinoid X receptors (RXRs), and ac-
tivation of RXR-PPARγ favours the differentiation of adipo-
cyte progenitors and preadipocytes in adipose tissue and reg-
ulates lipid biosynthesis and storage [53]. In contrast, activa-
tion of the RXR-PPARα heterodimer stimulates β-oxidation
breakdown of fatty acids [54]. Several EDCs have now been
shown to alter adipogenesis through interfering in PPARγ
actions [55].
Both tributyltin and triphenyltin are nanomolar affinity li-
gands for the RXR-PPARγ heterodimer [30, 56] and stimulate
3T3-L1 preadipocytes to differentiate into adipocytes [30, 56,
57] in a PPARγ-dependent manner [58, 59]. Using the same
3T3L1 cell model, BPA [60], nonylphenol [61] and the fun-
gicide triflumizole [62] have also been shown to promote
adipogenesis. The phthalate metabolite mono(2-ethyl-
hexyl)phthalate is a known potent and selective activator of
PPARγ [63] that promotes the differentiation of 3T3-L1 cells
into adipocytes [64]. Although many phthalates show greater
responses through PPARα than on PPARγ [65], it may be the
metabolites which act through PPARγ that cause weight gain.
Phthalate metabolites in excess of several micrograms per litre
have been measured in over three quarters of urine samples
from the US population [66], and epidemiological studies
have noted an association between phthalate metabolites and
Fig. 2 Exposure to
diethylstilbestrol (DES) during
the neonatal period predisposes to
obesity in mice at 4–6 months of
age. Reproduced from Newbold
et al. [99], with permission from
Elsevier
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increased waist circumference [67, 68]. More recent work has
reported that benzyl butyl phthalate can promote adipogenesis
in 3T3-L1 preadipocytes [69], and so there may be some var-
iation between different esters.
Parabens have also been shown to promote adipocyte dif-
ferentiation in 3T3-L1 cells [70]. Adipogenic potency in-
creased with the linear length of the alkyl chain [70] and
was associated with PPARγ activation [71]. It now appears
likely that any ligand which can bind to the PPARγ will be
able to influence adipogenesis and obesity [71]. Since so
many of such ligands are present in human adipose tissue, it
is probable that they may also be able to act in combination
through additive mechanisms. This may then enable mixtures
of such ligands to stimulate adipogenesis at lower concentra-
tions than needed for each alone. Such additive effects are
recognised for other endocrine-disrupting mechanisms, most
notably in the context of combinations of oestrogenic com-
pounds acting via oestrogen receptors to increase proliferation
of oestrogen-responsive cells [2•].
Obesogens Acting through Interference with Steroid
Receptors
Steroid hormones can influence lipid storage and fat deposi-
tion and can therefore also impact on adipose tissue develop-
ment [72]. Hormone replacement therapy based on oestrogens
can protect against many age-related changes in adipose depot
remodelling at menopause [73]. Dietary soy phytoestrogens,
such as genistein and daidzein, modulate oestrogen receptor
signalling and reverse truncal fat accumulation in postmeno-
pausal women [74], an effect which has been demonstrated
also in ovariectomized rodent models [75]. However, foetal or
neonatal oestrogen exposure can have the opposite effect and
lead to obesity later in life, which emphasises, again, that
timing of exposure can be important in the consideration of
outcomes. Rodents treated with phytoestrogens during
pregnancy or lactation were observed to develop obesity at
puberty [76], especially in males [77], which might question
the wisdom of consumption of soy-based products by baby
boys. Neonatal exposure of female mice to the synthetic
oestrogen DES initially led to depressed body weight, but
was followed by long-term weight gain in adulthood [78,
79], although notably not in male mice [80], demonstrating
the obesogenic effect of a potent oestrogen on adipogenesis
which can be gender-specific.
Whilst some EDCs may act directly through cellular ste-
roid receptors, other EDCsmay act less directly by stimulating
oestrogen synthesis. Adipose tissue is known to be a site of
oestrogen synthesis, and the cytoplasm of adipocytes contains
the cytochrome P450 enzyme aromatase which converts tes-
tosterone to oestrogens. Several EDCs are now known to be
able to influence intracellular aromatase activity [81] and
could therefore act indirectly to raise the intracellular levels
of oestrogen in adipocytes with a consequent increase in obe-
sity not only in women but also in men [82].
Obesogens Act through Aryl Hydrocarbon Receptors
The aryl hydrocarbon receptor (AhR) is a ligand-activated
transcription factor that senses the presence of foreign com-
pounds such as POPs and leads to the activation of cyto-
chrome P450 enzymes needed for their clearance from the
body [2•]. However, AhR can indirectly influence adipogen-
esis through altering PPARγ expression, and some POPs with
obesogenic activity, which can be inhibited by AhR antago-
nists, have been suggested to function through this mechanism
of action [32].
Obesogens Act by Altering Recruitment of Fat Cells
Mature adipocytes are generated from multipotent stromal
cells (MSCs) of foetal and adult tissues [83]. These MSCs
Fig. 3 Summary of the
mechanisms of action of
obesogenic endocrine disruptors
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can differentiate into several different cell types in vitro, includ-
ing not only adipose tissue but also bone, cartilage and muscle,
and regulation of these processes is essential for homeostasis.
Exposure of pregnant mice to TBT has been shown to result in
MSCs which differentiate in offspring preferentially into adipo-
cytes rather than bone and, furthermore, which have epigenetic
alterations in the methylation status of some adipogenic genes
[58]. Similar results were obtained following prenatal exposure
to the fungicide triflumizole [62], which demonstrates that
some EDCs can act by altering recruitment as well as differen-
tiation of fat cells. A sensitive time for such alterations would be
during the development of adipose tissue in early life.
Obesogens act by altering appetite, satiety and food
preferences
Another mechanism of EDC action may be through altering the
energy balance between energy intake and energy expenditure,
especially by altering appetite, satiety and food preferences.
Although BPA has been shown to induce obesity in experimen-
tal studies [33] and is present in over 90% of urine samples in
the US population [84], no direct association has been
established between serum BPA levels and amount of body
fat [85]. However, more recently, BPA levels have been found
to correlate in humans with circulating levels of leptin and
ghrelin [86•]. These are hormones secreted by the adipose tissue
which act in opposing ways to regulate hunger, with leptin
being inhibitory and ghrelin being stimulatory. Alterations to
the circulating levels of these hormones suggest that BPA may
be able to act by interfering with hormonal control of hunger
and satiety [86•], which is corroborated by a recent report of
increased production of leptin mRNA in a 3T3L1 adipocyte
model after 3 weeks of exposure to 1 nMBPA [87]. In a mouse
model, post-weaning exposure to methylparaben also increased
serum leptin levels [36•], which begs the question as to whether
any association between paraben exposure and leptin levels
might be observed in human studies.
The Vicious Spiral of Obesogenic EDC Actions
and Human Health
Obesity is not just a matter of carrying excess weight through
life, but has been established as an underlying risk factor for
many diseases including metabolic syndrome [88], diabetes
[89], cardiovascular disease [90] and cancer [91].
Coincidentally, development of many of these diseases has also
been linked to exposure to EDCs [2•]. In this context, it is
noteworthy that many EDCs are lipophilic, and POPs in partic-
ular are known to bioaccumulate in body fat over the years. It is
therefore plausible that the link of obesity to disease relates not
just simply to the deposition of fat but to the increased retention
of lipophilic pollutants in the greater volume of fat. Figure 4
illustrates the potential for a “vicious spiral” to be set up where-
by obesogens act to increase the amount of fat stored (be it by
increased cell volume or increased cell number), which would
be followed by greater retention of lipophilic obesogens and
which would then lead onward in an increasing spiral of greater
body fat and even more lipophilic pollutant retention. In this
sense, obesogens may be self-fulfilling and be able to increase
capacity for their own retention.
Although such a mechanism may enable obesity to be asso-
ciated with a greater body burden of obesogens, there are also
many other lipophilic pollutant chemicals which have adverse
effects on the human body other than through their obesogenic
activity. Therefore, the obesogenic nature of some EDCs may
enable increased storage of a wide range of other lipophilic
environmental pollutants with adverse properties, including
non-obesogenic EDCs and non-obesogenic non-EDC environ-
mental chemicals. Retention of such a complex mixture of pol-
lutant chemicals offers the potential for additive or complemen-
tary mechanisms to aggravate disease processes. For example,
in considering the hallmarks of cancer [92], whilst sustained
proliferation of endocrine-regulated cancers may be driven by
EDCs, other environmental chemicals may be needed to drive
other cancer hallmarks, and genotoxic chemicals will be needed
to cause the underlying mutations and genomic instability as-
sociated with cancer cells. For these reasons, the obesogenic
activity of EDCs may have an even wider impact on disease
processes than currently accredited.
One caveat is that the biological availability of the retained
compounds in the fatty tissues/cells remains poorly understood.
Whilst it is often assumed that xenobiotics retained in fatty
deposits of the body would be sequestered, some xenobiotics
are known to form fatty acid conjugates which themselves exert
local toxicities [93]. Conjugate formation is a metabolic mech-
anism used to increase hydrophilicity to aid elimination from
the body. Common conjugates are with sulphate, glucuronic
acid, glutathione or amino acids, and this is also often assumed
to negate biological activity. However, for phytoestrogens,
whilst sulphation of some does negate oestrogenic activity,
sulphation of others can enhance oestrogenic activity [94],
and some glucuronide conjugates also retain oestrogenic activ-
ity [95]. Although BPA-glucuronide lacks oestrogenic activity,
it has been reported as still capable of promoting adipogenesis
[96]. The biological availability of pollutants retained in fat is
therefore an unresolved aspect which needs further research and
specific research to take account not only of enzymatic
deconjugation to the free form but also the activity of conju-
gates themselves.
A further consideration is of the consequence of the timing
of exposure to the obesogenic EDCs. Since obesogen expo-
sure in utero or during early postnatal life can increase fat cell
number permanently into adult life [4•, 51], it follows that
early-life exposure to obesogens could result in a greater life-
time burden of lipophilic pollutants. Whilst the release of
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lipophilic pollutants in breast milk fat during breastfeeding
may serve to detoxify the mother’s breasts, adverse conse-
quences for the baby have long been a concern [97, 98].
However, sudden weight loss, such as through dieting, could
also cause the release of lifetime bioaccumulated pollutants
from body fat with untoward consequences if the release were
too fast for the body to eliminate the compounds sufficiently
quickly. A final unanswered question relates to whether pol-
lutant retention may relate to body fat composition as well as
quantity of body fat, and therefore whether there may be dif-
ferent consequences arising not just from variations in expo-
sure to EDCs by differing lifestyles but also from variations in
the retention of EDCs according to the specific fat composi-
tion laid down in the adipocytes.
Conclusions and Implications for Risk Assessment
of Obesogenic EDCs
The weight of evidence pointing towards a role for EDCs in
influencing obesity offers not just a mechanistic understand-
ing of the obesity crisis but also a strategy for prevention.
Although, undoubtedly, overeating coupled with lack of
exercise is a major contributor to the rise in obesity, which
can be resolved by reduced calorie intake and increased
exercise, it may be that reduction in exposure to obesogenic
EDCs, particularly during early life stages, could also con-
tribute to reducing obesity in the population. This will re-
quire a political will to limit the use of some of the
offending chemicals and an education programme in mater-
nity clinics so that there is a more general understanding of
the consequences of exposure to obesogens in early life.
Although many of these EDCs were originally developed
for a range of beneficial uses, their potential for contributing
to obesity needs now to be added into risk assessment of
EDCs, and the widespread exposure of the human popula-
tion to so many EDCs with obesogenic activity requires
assessment of the effects not only of individual chemicals
but of the complex mixtures entering human tissues from
varied lifestyle choices. However, perhaps one of the bene-
fits of this research and its widespread dissemination in the
popular media is that informed individuals can also act on a
precautionary principle to reduce exposure of themselves
and their children ahead of any regulatory actions and there-
fore have some degree of self-determination in their own
exposure to such EDCs.
Fig. 4 The “vicious spiral” of
obesogenic activity and lipophilic
properties of endocrine
disruptors. The obesogenic
activity of endocrine-disrupting
chemicals (EDCs) results in
increased body fat: since EDCs
are lipophilic, more EDCs will be
stored as the amount of body fat
increases. This may cause an
upwards spiral towards increasing
body fat and, therefore, increasing
body burden of EDCs, and indeed
of other lipophilic environmental
pollutant chemicals as well
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